Status: current, Not sufficiently defined by necessary conditions definition status (core metadata concept). Date: 31-Oct 2016. Module: Canada Health Infoway English module (core metadata concept)
Descriptions:
| Id | Description | Lang | Type | Status | Case? | Module |
| 137471000087118 | Menomune-A/C 50 micrograms group A and 50 micrograms group B per 0.5 milliliter powder and diluent for suspension for injection Connaught Laboratories Inc. (real clinical drug) | en | Fully specified name | Active | Entire term case sensitive (core metadata concept) | Canada Health Infoway English module (core metadata concept) |
| 71841000087110 | Men-P-AC Menomune-A/C CLL | en | Synonym (core metadata concept) | Active | Entire term case sensitive (core metadata concept) | Canada Health Infoway English module (core metadata concept) |
| 71861000087111 | Menomune-A/C 50 micrograms group A and 50 micrograms group B per 0.5 milliliter powder and diluent for suspension for injection Connaught Laboratories Inc. | en | Synonym (core metadata concept) | Active | Entire term case sensitive (core metadata concept) | Canada Health Infoway English module (core metadata concept) |
| Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values |
| Menomune-A/C 50 micrograms group A and 50 micrograms group B per 0.5 milliliter powder and diluent for suspension for injection Connaught Laboratories Inc. (real clinical drug) | est un(e) (attribut) | Product manufactured as parenteral dose form (product) | true | Inferred relationship | Some | ||
| Menomune-A/C 50 micrograms group A and 50 micrograms group B per 0.5 milliliter powder and diluent for suspension for injection Connaught Laboratories Inc. (real clinical drug) | a une forme pharmaceutique (attribut) | forme pharmaceutique pour usage parentéral (forme pharmaceutique) | true | Inferred relationship | Some | ||
| Menomune-A/C 50 micrograms group A and 50 micrograms group B per 0.5 milliliter powder and diluent for suspension for injection Connaught Laboratories Inc. (real clinical drug) | Count of active ingredient | deux | false | Inferred relationship | Some | ||
| Menomune-A/C 50 micrograms group A and 50 micrograms group B per 0.5 milliliter powder and diluent for suspension for injection Connaught Laboratories Inc. (real clinical drug) | a pour principe actif (attribut) | Antigen of Neisseria meningitidis serogroup C capsular polysaccharide unconjugated (substance) | true | Inferred relationship | Some | 2 | |
| Menomune-A/C 50 micrograms group A and 50 micrograms group B per 0.5 milliliter powder and diluent for suspension for injection Connaught Laboratories Inc. (real clinical drug) | Has supplier | Connaught Laboratories Inc. (supplier) | true | Inferred relationship | Some | ||
| Menomune-A/C 50 micrograms group A and 50 micrograms group B per 0.5 milliliter powder and diluent for suspension for injection Connaught Laboratories Inc. (real clinical drug) | Count of base of active ingredient | un | false | Inferred relationship | Some | ||
| Menomune-A/C 50 micrograms group A and 50 micrograms group B per 0.5 milliliter powder and diluent for suspension for injection Connaught Laboratories Inc. (real clinical drug) | Plays role | Active immunity stimulant role (role) | true | Inferred relationship | Some | ||
| Menomune-A/C 50 micrograms group A and 50 micrograms group B per 0.5 milliliter powder and diluent for suspension for injection Connaught Laboratories Inc. (real clinical drug) | a pour principe actif (attribut) | Antigen of Neisseria meningitidis serogroup A capsular polysaccharide unconjugated | true | Inferred relationship | Some | 1 | |
| Menomune-A/C 50 micrograms group A and 50 micrograms group B per 0.5 milliliter powder and diluent for suspension for injection Connaught Laboratories Inc. (real clinical drug) | est un(e) (attribut) | Vaccine product containing only meningococcal groups A + C capsular polysaccharide unconjugated antigens (medicinal product) | true | Inferred relationship | Some | ||
| Menomune-A/C 50 micrograms group A and 50 micrograms group B per 0.5 milliliter powder and diluent for suspension for injection Connaught Laboratories Inc. (real clinical drug) | a pour principe actif (attribut) | Meningococcus vaccine (substance) | false | Inferred relationship | Some | 1 |
| Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group |
This concept is not in any reference sets
FHIR